Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1992-2-27
|
pubmed:abstractText |
There is continued interest in the development of oral beta-lactam compounds, which can be used clinically to treat various bacterial infections, particularly those caused by beta-haemolytic streptococci. Cefixime is a new orally active cephalosporin, with a broad spectrum of antibacterial activity, including Enterobacteriaceae, Haemophilus influenzae, Branhamella catarrhalis, Streptococcus pneumoniae and Streptococcus pyogenes. Cefixime is highly resistant to hydrolysis by most beta-lactamases. In this study the authors examined the effects of this molecule on Group A and Group B beta-haemolytic streptococci, recently isolated from clinical specimens in the authors' laboratory. MICs and the growth curves of 36 strains of Group A streptococci and the effects of sub-MICs on buccal cell adhesion were evaluated. The results show that concerning the sub-MIC cefixime effect on streptococci adherence, the treatment led to a decrease in adherence to the cells of the strains studied. Moreover cefixime showed good activity with 86.1% of the strains with MIC less than or equal to 0.5 microgram/ml, and the growth curves demonstrated that the molecule possesses a bactericidal effect after 3 h. Concerning Group B streptococci, 70.3% of the strains showed a MIC less than or equal to 2 micrograms/ml. In conclusion cefixime demonstrates good activity on beta-haemolytic streptococci, particularly those of Group A.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0378-6501
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
305-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1769318-Anti-Infective Agents, Urinary,
pubmed-meshheading:1769318-Cefixime,
pubmed-meshheading:1769318-Cefotaxime,
pubmed-meshheading:1769318-Cell Adhesion,
pubmed-meshheading:1769318-Cell Division,
pubmed-meshheading:1769318-Cheek,
pubmed-meshheading:1769318-Dose-Response Relationship, Drug,
pubmed-meshheading:1769318-Epithelial Cells,
pubmed-meshheading:1769318-Epithelium,
pubmed-meshheading:1769318-Microbial Sensitivity Tests,
pubmed-meshheading:1769318-Mouth Mucosa,
pubmed-meshheading:1769318-Streptococcus agalactiae,
pubmed-meshheading:1769318-Streptococcus pyogenes
|
pubmed:year |
1991
|
pubmed:articleTitle |
Cefixime shows good effects on group A and group B beta-haemolytic streptococci.
|
pubmed:affiliation |
Institute of Microbiology, University of Reggio Calabria, Catanzaro, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|